Email
Password
Remember meForgot password?
    Log in with Twitter
Press Release

Feb 5, 2019 16:13 UTC

Global Dravet Syndrome Market: Industry Analysis & Outlook (2019-2023) - Attractive Orphan Drug Policies & Rising Strategic Alliances are Key Drivers - ResearchAndMarkets.com

DUBLIN--(Business Wire)--The "Global Dravet Syndrome Market: Industry Analysis & Outlook (2019-2023)" report has been added to ResearchAndMarkets.com's offering.

The disorder is considered orphan indication, and there are very limited treatment options available in the market. However, several therapeutics for Dravet syndrome are in pipeline. The drugs in development are getting orphan drug designation by FDA and EMA.

The Dravet syndrome market in Europe and the U.S. is likely to exhibit significant growth in the next five years due to increasing research and development activities conducted by several companies. Several companies are making alliances for developing therapeutics for Dravet syndrome.

Currently, the U.S. and Europe are holding the potential growth for Dravet Syndrome market due to increasing R&D into new drug development for Dravet syndrome and approval for these drugs in these regions.

Key players of the market include Zogenix, Zynerba, GW Pharmaceuticals, and OPKO. Currently, only GW Pharmaceuticals' Epidiolex is commercially available.

Other players are currently developing their drugs or seeking for commercial approval by FDA and EMA. Zogenix's ZX008 is expected to penetrate market in 2019 and create competition for GW Pharmaceuticals. Currently, the market is dominated by generic drugs.

Dravet Syndrome

Dravet syndrome, formerly known as severe myoclonic epilepsy of infancy (SMEI), is a severe kind of epilepsy which causes seizures. High fever is usually a trigger for these seizures. It is a rare disorder that affects an estimated 1 in every 20,000-40,000 births.

It usually develops in the sixth month of age. It is caused by loss-of-function mutations in one copy of the SCN1A gene. Patients with Dravet syndrome are not able to produce sufficient levels of functional Nav1.1 sodium channel, preventing inhibitory neurons from firing properly.

Topics Covered

1. Overview

1.1 Dravet Syndrome

2. Global Dravet Syndrome Drug Market

2.1 ZX008 Sales Value Forecast

2.2 Epidiolex Sales Value Forecast

3. Regional Dravet Syndrome Drug Market

3.1 The U.S.

3.1.1 The U.S. Dravet Syndrome Patient Volume Forecast

3.1.2 ZX008 Sales Value Forecast in the U.S. Dravet Syndrome Market

3.1.3 Treated Dravet Syndrome Patients with ZX008 in the U.S. Forecast

3.1.4 ZX008 Penetration Forecast in the U.S. Dravet Syndrome Market

3.1.5 Epidiolex Sales Value Forecast in the U.S. Dravet Syndrome Market

3.1.6 Treated Dravet Syndrome Patients with Epidiolex in the U.S. Forecast

3.1.7 Epidiolex Penetration Forecast in the U.S. Dravet Syndrome Market

3.2 Europe

3.2.1 Europe Dravet Syndrome Patient Volume Forecast

3.2.2 ZX008 Sales Value Forecast in Europe Dravet Syndrome Market

3.2.3 Treated Dravet Syndrome Patients with ZX008 in Europe Forecast

3.2.4 ZX008 Penetration Forecast in Europe Dravet Syndrome Market

3.2.5 Epidiolex Sales Value Forecast in Europe Dravet Syndrome Market

3.2.6 Treated Dravet Syndrome Patients with Epidiolex in Europe Forecast

3.2.7 Epidiolex Penetration Forecast in Europe Dravet Syndrome Market

4. Market Dynamics

4.1 Growth Drivers

4.1.1 Attractive Orphan Drug Policies

4.1.2 Rising Healthcare Expenditure

4.1.3 Accelerating Economic Growth

4.1.4 Rising Strategic Alliances

4.2 Key Trends

4.2.1 Development of New Therapeutics

4.2.2 Approval of Cannabidiol Drugs for Dravet Syndrome

4.3 Challenges

4.3.1 Regulatory Challenges

4.3.2 Associated Risks

4.3.3 Insufficient Disease Information and Research Participants

4.3.4 Rising Competition from Generic Industry

5. Competition

5.1 Global Market

5.1.1 Revenue Comparison of Key Players

5.1.2 Market Cap Comparison of Key Players

5.1.3 Comparison of Epidiolex and ZX008

6. Company Profiles

6.1 Zogenix

6.1.1 Business Overview

6.1.2 Financial Overview

6.1.3 Business Strategies

6.2 Zynerba

6.3 OPKO

6.4 GW Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/research/rb6fch/global_dravet?w=4

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs

Latest News
Top News